Here's what Jim Cramer had to say about some of the stocks during the Mad Money Lightning Round:
Aimmune Therapeutics (AIMT) : "I do like it. That's an important niche business. "
Cramer and the AAP team are looking for opportunities to trim stocks into strength based out of discipline. That means trimming Magellan Midstream Partners (MMP - Get Report) . Find out what they're telling their investment club members and get in on the conversation with a free trial subscription to Action Alerts PLUS.
Over on Real Money, Cramer talks more about the 10-year crossing 3%. Get more of his insights with a free trial subscription to Real Money.
Search Jim Cramer's "Mad Money" trading recommendations using our exclusive "Mad Money" Stock Screener.
To read a full recap of this episode of "Mad Money," click here.
To watch replays of Cramer's video segments, visit the Mad Money page on CNBC.
To sign up for Jim Cramer's free Booyah! newsletter with all of his latest articles and videos please click here.